Life Sciences has been saved
New businesses, new markets
It has been another challenging year for the global life science industry. Economic crisis in Europe, pricing pressures, reputational hits, and a perceived lack of transparency in clinical trial reporting are just a few. Yet opportunities for the industry abound–in the fast emerging markets beyond the BRICs, personalized medicine, and in harnessing ‘the power of networks’ to transform R & D. How will the industry rise to the challenge?
The Financial Times 2013 Pharmaceutical & Biotechnology Conference
On 3-4 December 2013, over 200 life sciences executives will gather in London to discuss today's pressing industry issues at the FT Pharma/Biotech Conference. Listen to our podcast as Pete Mooney, DTTL Global Life Sciences (LSHC) Industry Leader; and Mike Standing, DTT European Regional LSHC Industry Leader, discuss several of the topics and on the conference agenda and share their perspectives on the future direction of the industry.